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Abstract
Background Vaccination against tumour-associated anti-
gens is one approach to elicit anti-tumour responses. We
investigated the effect of polynucleotide (DNA) vaccination
using a model antigen (E. coli lacZ) in a syngeneic gliosar-
coma model (9L).
Methods Fisher 344 rats were vaccinated thrice by intra-
muscular injection of a lacZ-encoding or a control plasmid
in weekly intervals. One week after the last vaccination,
lacZ-expressing 9L cells were implanted into the striatum.
Results After 3 weeks, in lacZ-vaccinated animals
the tumours were significantly smaller than in control-
vaccinated animals. In cytotoxic T cell assays lysis rates of
>50 % could only be observed in a few of the lacZ-
vaccinated animals. This response was directed against
lacZ-expressing and parental 9L cells but not against syn-
geneic MADB 106 adenocarcinoma cells. In Elispot assays
interferon-γ production was observed upon stimulation with
9LlacZ and 9L wild-type but not MADB 106 cells. This
response was higher for lacZ-immunized animals. All ani-
mals revealed dense infiltrates with CD8+ lymphocytes and,
to a lesser extent, with NK cells. CD25-staining indicated
cells possibly associated with the maintenance of peripheral
tolerance to self-antigens. All tumours were densely infil-
trated by microglia consisting mostly of ramified cells. Only
focal accumulation of macrophage-like cells expressing
ED1, a marker for phagocytic activity, was observed.
Conclusion Prophylactic DNAvaccination resulted in effec-
tive but incomplete suppression of brain tumour formation.
Mechanisms other than cytotoxic T cell responses as
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measured in the generally used in vitro assays appear to play
a role in tumour suppression.
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Introduction
Malignant gliomas cannot be cured despite technical devel-
opments aiding surgical resection techniques, optimised ra-
diotherapy, and novel (local and systemic) chemotherapy.
However, we have obtained broad knowledge regarding
molecular alterations involved in glioma formation and tu-
mour maintenance. This has fostered the search for novel
adjuvant therapies, including gene therapy and immunother-
apy, which have been pursued in several preclinical and
clinical studies. However, a relevant survival benefit has
not been achieved to date [2, 4].
Malignant gliomas are highly infiltrative tumours
contributing to their inevitable recurrence. Specific ac-
tivation of the immune system has always been
regarded as a worthwhile attempt in order to eliminate
residual tumour cells by immuno surveillance. Several
approaches have been utilised, including transfer of
adoptive T cells, peptide immunization, and vaccination
with dendritic cells pulsed with tumour-derived proteins
or nucleic acids [9, 16].
Polynucleotide (DNA) vaccination represents another
straightforward approach with possible advantages. In con-
trast to immunisation with peptides, DNA vaccination
appears to result in stronger cytotoxic, Th1-mediated
responses that are regarded as crucial for effective anti-
tumour effects [3, 18]. Furthermore, the vaccine, i.e., the
expression plasmids, can be readily produced in large quan-
tities, and it is possible to immunise with the whole cDNA,
obviating the need to characterise and synthesise specific
epitopes. To evaluate this vaccination concept in a brain
tumour model, we used a model antigen (E. coli lacZ) for
repeated intramuscular vaccination prior to intracerebral




The 9L rat gliosarcoma cells were obtained from the
Brain Tumour Research Center, University of California,
San Francisco, CA, USA. MADB 106 rat adenocarcino-
ma cells were a kind gift from Dr. Thomas von
Hörsten, Medizinische Hochschule Hannover, Germany.
Both cell lines are syngeneic to Fisher 344 rats. 9LlacZ
cells had been transfected with the LNPOZ vector
(kindly provided by Dr. A.D. Miller, Seattle, WA) con-
taining the E. coli lacZ gene and the neomycin resis-
tance gene. The latter served for selection of stable
lacZ-expressing cells by selection with G418 after trans-
fection with EffecteneTM (Qiagen, Hilden, Germany).
Cells were cultured in DMEM supplemented with
2 mML-glutamine, 1,000 mg/l D-glucose, and 2 mM
sodium pyruvate (GIBCO BRL Life Technologies,
Karlsruhe, Germany; 9L and 9LlacZ cell lines) or
RPMI (GIBCO BRL Life Technologies, Karlsruhe,
Germany; MADB 106 cell lines) containing both 10 %
heat-inactivated foetal calf serum and 1 % penicillin/
streptomycin (Sigma-Aldrich, St. Louis, MO, USA) at
37 °C in a humid atmosphere with 5 % CO2.
Plasmids
DNA vaccination against the lacZ antigen was per-
formed with a lacZ-containing expression vector
(pcDNA3.1/His B/lacZ; Invitrogen, Karlsruhe, Germany).
Control animals were injected with an empty expression
vector (pcDNA3.1/His B; Invitrogen, Karlsruhe,
Germany). To prevent vaccination against the neomycin
resistance gene, this gene had been deleted from both
plasmids, and vector integrity was confirmed by se-
quence analysis. Large-scale preparation of plasmid
DNA was performed with the EndoFree GigaPrep®
(Qiagen, Hilden, Germany). DNAwas solved in 0.9 % sterile
saline and stored in aliquots at –20 °C.
Vaccination protocol and tumour cell implantation
Male Fisher 344 rats (250 to 275 g) were purchased
from Charles River (Sulzfeld, Germany). Animals were
housed according to German Animal Protection
Regulations, and permission had been obtained from
the local authorities. Weekly vaccinations into both an-
terior tibial muscles were performed thrice with 100 μg
DNA per leg in a volume of 50 μl normal saline. One
week after the last vaccination, animals were anaesthe-
tised with 4 % chloral hydrate (1 ml per 100 g) and the
heads were mounted into a stereotactic frame (TSE
Systems, Bad Homburg, Germany). A burr hole was
placed 3 mm lateral and 1 mm anterior to the bregma,
and 2 × 104 9L/lacZ cells suspended in 5 μl DMEM
without supplements were slowly injected into the right
striatum with a 10-μl Hamilton syringe. The needle was
carefully retracted and the burr hole was sealed with
bone wax. After 3 weeks animals were killed and
spleens were removed under sterile conditions and
kept in ice-cold RPMI containing 10 % FCS until
52 Acta Neurochir (2013) 155:51–59
lymphocyte preparation. Blood was collected from the
right atrium, and brains were removed and transferred
into anti-freeze medium (Reichert-Jung, Nussloch,
Germany), shock-frozen in liquid nitrogen, and stored
at –20 °C.
Histology and immunohistochemistry
The tumour volume was calculated from serial
hemalaun-eosin-stained sections (200 μm distance) using the
following formula: V 0 4/3 x π × 0.125 (length × height ×
width). Coronal sections of 10 μm were cut with a
cryostat 2800 Frigocut (Reichert-Jung, Nussloch,
Germany), and we identified sections where the tumour
appeared first and where it disappeared. For immuno-
histochemical and X-Gal staining, brain slices were
mounted on coated slides (Marienfeld GmbH, Lauda-
Königshofen, Germany), air-dried, and stored at –20 °C in
aluminium foil.
The 9L cells expressing the lacZ gene convert X-Gal
to 5,5′-dibromo-4,4′-dichloro-indigo, staining the cyto-
plasm of these cells blue. Brain slices were fixed with
10 % formaldehyde for 10 min and washed twice with
PBS. Staining with X-Gal was performed in a moist
chamber at 37 °C overnight. Slides were washed in
PBS twice for 5 min and covered with Aquatex
(Merck, Darmstadt, Germany).
Immunohistochemical staining was performed according
to Barclay et al. [1]. Slices were fixed in acetone at – 20 °C
for 10 min and rinsed in tap water for 1 min. To eliminate
endogenous peroxidase, slices were transferred into PBS/
methanol (1:1) containing 0.3 % H2O2 and washed thrice
with PBS. Immunohistochemistry was performed with the
following mouse anti-rat monoclonal antibodies (obtained
from Serotec, Oxford, UK; all antibodies diluted 1:400):
W3/25 (anti-rat CD4), MRC OX-8 (anti-rat CD8), MRC
OX-39 (anti-rat CD25), R73 (anti-rat αβ T-cell receptor),
10/78 (anti-rat NKR-P1), and ED1 (anti-rat CD68). In addi-
tion, the following rabbit anti-rat polyclonal antibodies were
used: anti-perforin (Torrey Pine Biolabs, San Diego, CA;
dilution 1:400) and Iba1 directed against an ionised
calcium-binding adaptor molecule-1 expressed in microglia
and macrophages (kind gift from Y. Imai, Department of
Neurochemistry, National Institute of Neuroscience, Tokyo;
dilution 1:1,500). Incubation with the primary antibodies in
PBS with 1 % bovine serum albumin (Sigma-Aldrich,
Munich, Germany) was performed at 4 °C overnight.
Slices were washed three times with PBS and incubated
with the secondary biotinylated rabbit anti-mouse or
swine anti-rabbit antibody (Dako, Hamburg, Germany;
1:400), which was added in PBS with 10 % heat-
inactivated rat serum at 37 °C for 1 h. Slices were
washed and incubated with a streptavidine complex
(Dako, Hamburg, Germany; 1:300) in PBS at 37 °C
for 45 min, and 3,3′-diaminobenzidine (DAB; Dako,
Hamburg, Germany) served as the chromogene sub-
strate. After nuclear staining with hemalaun (Merck,
Darmstadt, Germany), slices were covered with
Aquatex (Merck, Darmstadt, Germany).
Cytotoxic T lymphocyte assay
Spleens were removed under sterile conditions and trans-
ferred to a petri dish (Becton Dickinson Labware, Franklin
Lakes, NJ, USA) to generate a cell suspension that was
passed through a 70-μm-pore filter (Becton Dickinson).
The cell suspension was layered onto Lympholyte M
(Cedar Lane, Ontario, Canada), and mononuclear cells were
isolated by density-gradient centrifugation with 1,000 g for
20 min. After washing thrice, cells were transferred to a petri
dish, and cells were allowed to adhere to the bottom at 37 °C
for 2 h. In contrast to monocytes/macrophages and B cells
that adhere to plastic, T cells can be collected by aspiration
off the culture media after gentle shaking. Cells were
washed twice with RPMI, and their viability was determined
by trypan blue staining. Usually 1-2 × 108 mononuclear
cells per spleen were obtained.
Generation of effector cells for the chromium release
assay was performed as described previously [17, 20].
In brief, 9L/lacZ cells serving as stimulator cells were
seeded in 6-well plates and irradiated with a lethal dose
of 40 Gy. T cell-enriched mononuclear cells (5 × 106)
were added at a ratio of 1:10, which proved optimal in
preliminary experiments, and co-cultures were incubated
for 7 days. On days 3 and 5, fresh RPMI (10 % FCS,
penicillin G/streptomycin) containing 30 U/ml human
recombinant Il-2 (Sigma-Aldrich, Munich, Germany)
was added.
On day 7, target cells (9L/lacZ, 9Lwt, or MADB106; 5 ×
105 cells) were labelled with 200 μCi Na51CrO4
(Amersham-Buchler, Braunschweig, Germany) in 1 ml
RPMI containing 10 % FCS in a shaking water bath at
37 °C for 1 h. After washing thrice to eliminate non-
incorporated Na51CrO4, cells were counted and viability
rates of >90 % were assured by trypan blue staining.
Target cells (TC) were adjusted to 30,000 cells/ml, distrib-
uted on 96-well round-bottom plates (Corning Incorporated,
Corning, NY, USA), and let to adhere for 2–3 h before
effector cells were added. Effector cells (EC) were collected,
counted, and added to labelled TC in fresh RPMI in differ-
ent ratios (10:1, 20:1, 40:1, 80:1) in triplicate. Contact
between target and effector cells was achieved by centrifu-
gation of plates for 3 min. Plates were incubated at 37 °C for
4 h. The radioactive supernatant containing released 51Cr
was soaked off with cotton wool (Scatron Titertek harvest-
ing system; Scatron, Suffolk, UK) and transferred to a
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Gamma counter (Canberra-Packard, Frankfurt, Germany).
Spontaneous release of 51Cr was determined from TC with-
out exposure to EC (equivalent to 0 % specific release).
Maximum (100 %) release of 51Cr was determined follow-
ing TC lysis with 10 % Triton-X detergent. Specific lysis
was calculated as follows:
Specific lysis %ð Þ ¼ 100 experimental cpmspontaneous cpmð Þ maximum cpmspontaneous cpmð Þ=½ 
IFN-γ synthesis (Elispot assay)
IFN-γ synthesis by stimulated T-cells was determined with
a commercially available Elispot kit (Diaclone, Besançon,
France) following the protocol provided by the manufactur-
er with minor modifications according to Heiser et al. [10].
In brief, PVDF 96-well plates were incubated with an anti-
rat IFN-γ antibody (capture antibody) at 4 °C overnight.
The next day, freshly isolated spleen cells (5 × 105 respond-
er cells per well) were washed and resuspended in RPMI
containing 10 % FCS and co-incubated in the INF-γ
antibody-precoated 96-well plates with 9L/lacZ, 9Lwt, and
MADB106 (105 stimulator cells per well). After incubation
at 37 °C for 20 h, the cells were removed from the plate, and
a biotinylated anti-rat IFN-γ antibody (detection antibody)
was added and detected with streptavidine-conjugated alka-
line phosphatase converting the substrate BCIP/NBT to a
blue dye. Dots were counted using the Bioreader system
(BIO-SYS GmbH, Karben, Germany).
Results
Intramuscular polynucleotide vaccination performed thrice
with a lacZ expression plasmid prior to implantation of lacZ
expressing tumour cells was associated with a strong anti-
tumour response. Whereas control vaccinated animals
revealed large tumours (183.7 mm3; SD 99.2), the residual
tumours in lacZ-vaccinated animals were significantly
smaller (18.9 mm3; SD 13.3; p<0.05) (Fig. 1) .
Representative tumours are shown in Fig. 2. Necrotic areas
and neovascularisation were observed, but almost no infil-
trating tumour growth (Fig. 2 s–u). Vaccination with saline
(no plasmid) resulted in the formation of tumours similar in
size to control vaccinated animals (data not shown). In the
lacZ group, one animal died because of apnea during anaes-
thesia for tumour cell implantation. In the control group, two
animals died from excessive tumour growth before the ex-
periment was terminated. In both animals, large tumours
were found at autopsy, although exact tumour volumes
could not be determined because of post-mortem artefacts.
Immunohistochemical staining revealed strong lympho-
cytic and microglial cell infiltrates in tumours of all animals
(Fig. 2). Regardless of the type of prior vaccination (control
vs. lacZ vector), the pattern of infiltration did not differ.
Dense T-cell infiltrates (TCR staining) were found within
tumours of both lacZ- (Fig. 2a) and control-vaccinated
(Fig. 2f) animals, which was pronounced at the tumour
margins and extended into peritumoral normal brain.
Characterisation of T-cell infiltrates showed predominantly
CD8+ T cells (Fig. 2 b and g). Staining for CD4 revealed
both lymphocytes as well as dense infiltrates with microglial
cells (Fig. 2c and h). All tumours also revealed NK cells that
were less abundant than T cells (Fig. 2e and k). Perforin
granula suggesting cytolytic activity of NK cells and T cells
could only be detected in single cells (Fig. 2r). All tumours
contained CD25+ cells, which probably represent regulatory
CD4+ (or CD8+) T cells involved in peripheral tolerance to
self-antigens (Fig. 2d and j).
Two types of microglial cells could be distinguished
following staining with Iba1, MHC 2, and ED1 (Fig. 2l-q).
First and foremost, all tumours were densely infiltrated with
microglial cells revealing a ramified phenotype. Such cells
could be detected by staining against the MHC2 or Iba1
antigen (Fig. 2 l,m,q). Besides this, small clusters of
macrophage-like cells were detected (Fig. 2 n–p). These
Fig. 1 Rat glioma tumour volumes 3 weeks after intracerebral implan-
tation of 9L lacZ cells following DNA vaccination. Animals had been
vaccinated thrice with an empty expression vector (‘control’) or a lacZ-
encoding vecor (‘lacZ’) in weekly intervals followed by intracerebral
tumour cell implantation. The number of treated animals is indicated.
Tumour volumes (mean and standard deviation) were determined from
serial coronal sections. *p< 0.001 (Student’s t test). In the lacZ group,
one animal died because of apnea during anaesthesia for tumour cell
implantation. In the control group, two animals died because of exces-
sive tumour growth before the experiment had been terminated. Mas-
sive tumour growth was verified by histology, although post-mortem
tissue artefacts prevented accurate measurements
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cells stained positive for ED1, which is detected on lyso-
somal membranes of cells of the mononuclear phagocytosis
system (Fig. 2 n–p). Thus, ED1 appears to represent a
microglial subpopulation with phagocytic activity or macro-
phages. In general, the intensity of ED1 staining was most
prominent around necrotic areas (Fig. 2n). Nonetheless,
islets of ED1-positive cells were also found in non-
necrotic areas (Fig. 2 o and p).
X-Gal staining was performed to assess β-galactosidase
expression in residual tumours (Fig. 2u). Positive staining
suggests that residual tumours in lacZ-vaccinated animals
were not due to selection against the lacZ gene (Fig. 2u).
To evaluate cytotoxic T cell activity directed against
the implanted tumours, CTL assays were performed
with lymphocytes generated from in vitro restimulated
spleen cell preparations. As determined by flow cytom-
etry, >70 % of the restimulated cells were CD3-positive
lymphocytes (approximately 33 % CD8+ and 52 %
CD4+ cells). Restimulated cells contained less than
1 % cells that stained positive for NKR-P1, which
was used to identify natural killer cells (data not
shown). Strong cytotoxic responses with lysis rates
of >50 % were only observed in few animals, all of
which had been vaccinated against the lacZ antigen
(Fig. 3). This cytotoxicity was specific for both
9LlacZ cells and the parental 9L cell line (Fig. 3). No
cell lysis was observed when another syngeneic cell
line, MADB 106 rat adenocarcinoma, was used as target
cells (Fig. 3). Although some lacZ-vaccinated animals
revealed strong cytotoxic activity, this did not correlate
with tumour size or lymphocytic infiltrates as well as
CD25 or perforin staining. Cell lysis was T cell receptor
(TCR)-dependent since addition of a monoclonal anti-
body against the rat TCR (R73; 1:200) 1 h prior to
target cell exposure suppressed release of labelled chro-
mium by >50 % (not shown). Less inhibition was
observed with monoclonal antibodies directed against
MHC 1 (30 % inhibition), CD8 (20 %), or CD4 (20 %).
Fig. 2 Immunohistochemical characterisation of T-cell infiltrates and
microglial cells detected in tumours from control-vaccinated and lacZ-
vaccinated animals. Tumours of control-vaccinated and lacZ-
vaccinated animals were heavily infiltrated with TCR+ cells (a and f)
that were predominantly CD8+ lymphocytes (b and g). The same
region also contained moderate NK cell infiltrates (e and k). Staining
for CD4 revealed dense infiltrates with cells representing CD4+ lym-
phocytes and microglial cells, which could also be detected in the
peritumoral brain parenchyma (c and h). Microglial cells stained
MHC 2 positive (q), and staining for a microglial-specific marker
(Iba1) revealed the abundance of microglial cells both within the
tumour and in the peritumoral brain parenchyma (l and m). ED1
staining, a marker indicating phagocytic activity, mostly revealed focal
expression (n–p), in particular in necrotic regions (n). Perforin serving
as a marker for cytotoxic activity of NK and CD8+ cells revealed only
a few positive cells within the tumour (r). The cells staining positive
for CD25 probably represent regulatory CD4+ cells involved in the
maintenance of peripheral tolerance (d and j). Representative coronal
brain sections were stained with haematoxylin and eosin, indicating
large tumours in control animals (s) and markedly smaller tumours in
the lacZ-vaccinated animals (t and u). The smaller tumours in the lacZ-
vaccinated animals stained with X-Gal, indicating that selection against
the lacZ antigen had not occurred (u)
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Specific responses directed against 9LlacZ and paren-
tal 9L cells (but not MADB 106) were also observed in
several animals of the control group (Fig. 3). These
animals had not been vaccinated against the lacZ anti-
gen but exposed to 9LlacZ cells (intracerebral tumours).
In control animals, however, the lysis rates remained
below 25 % (Fig. 3). Lymphocytes derived from naive
animals neither vaccinated nor exposed to tumour cells
did not elicit cytolytic activity against any of the three
target cell lines (Fig. 3).
To further investigate anti-tumour immune responses,
IFN-γ synthesised by splenic lymphocytes exposed to
9LlacZ, 9L wild-type or MADB 106 cells was quanti-
fied by Elispot analysis. IFN-γ was produced by lym-
phocytes from lacZ-vaccinated as well as control-
vaccinated animals when stimulated with 9LlacZ or the
parental 9L cell line, but not following exposure to
syngeneic MADB 106 cells (Fig. 4). The amount of
IFN-γ synthesized was higher upon stimulation with
9L than 9LlacZ cells, which was independent of the
vaccination status (Fig. 4). Although prior lacZ vacci-
nation resulted in higher IFN-γ synthesis with both
9LlacZ or wild-type 9L stimulator cells, this was not
statistically significant (p > 0.05; ANOVA). The level of
IFN-γ production by lymphocytes of individual animals
and the size of their tumours did not correlate.
Discussion
This study demonstrates that intramuscular DNA vaccina-
tion against a model antigen (lacZ) suppresses the formation
of intracerebral tumours in a syngeneic rat model. Whereas
Fig. 3 Cytotoxic T cell assays with lymphocytes prepared from
spleens of untreated, control-vaccinated, or lacZ-vaccinated animals.
Splenocytes were restimulated for 6 days with 9LlacZ cells and added
to 51Cr-labelled target cells (9LlacZ, filled diamonds; 9L wild-type,
open diamonds; MADB, open triangles). The percentage of target cell
(TC) lysis in relation to different effector-target cell ratios (E:T-Ratio)
is shown for representative animals of each group. Whereas high levels
of 51Cr-release (>50 %) could only be observed in lacZ-vaccinated
animals (lacZ #1 and lacZ #2), specific but weaker lysis (<25 %) of
9LlacZ and parental 9L cells was also detected in control-vaccinated
animals (control #1). DNA vaccination against lacZ did not result in a
lacZ-restricted response. CTL activity directed against 9LlacZ cells
was always paralleled by a similar response against the parental 9L
cell line. However, cytotoxic activity was restricted to the 9L cell line
and not observed with another syngeneic cell line (MADB)
Fig. 4 Quantification of IFN-γ synthesis by the Elispot assay per-
formed with splenocytes isolated from control-vaccinated (filled bars)
or lacZ-vaccinated (open bars) animals. IFN-γ synthesis was observed
in lymphocytes derived from both control-vaccinated and lacZ-
vaccinated animals following exposure to 9LlacZ cells or the parental
9L cell line for 20 h. No such response was observed with a syngeneic
rat adenocarcinoma cell line (MADB). Although IFN-γ production
was higher in lacZ-vaccinated animals, this did not reach statistical
significance (p>0.5; ANOVA). The amount of IFN-γ detected was
higher following exposure to 9L cells compared to 9LlacZ cells. Bars
indicate standard deviations
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in the control vaccinated animals large tumours were
detected (including two animals which had died from ex-
cessive tumour growth), in the lacZ-vaccinated animals only
small tumours had formed. We did not quantify the efficacy
of vector uptake at the vaccination site. Although this
appears unlikely, we cannot rule out that more effective
uptake of the lacZ expression plasmid in conjunction with
unspecific (lacZ-independent) immune stimulation was
resposible for the decreased tumour size in the lacZ-
vaccinated animals.
We chose a point of time 3 weeks after intracerebral
tumour cell inoculation to assess tumour growth since this
was sufficient for the formation of large tumours in the
control-vaccinated group. Although at this point significant-
ly smaller tumours were found in the vaccinated animals,
tumour formation had not been prevented completely. We
cannot rule out that the small tumours detected in the
vaccinated animals on the day of sacrifice represent
tumour remnants during an ongoing process of tumour
rejection. However, it appears more likely that after com-
pleted preventive vaccination tumour rejection had oc-
curred directly after tumour cell inoculation (i.e. solid
tumour formation had been prevented altogether). The fact
that solid tumours were observed at all argues in favour of
an insufficient immune response merely delaying or
retarding tumour growth. Others have reported long-term
survival in a murine brain tumour model following DNA
vaccination [12]. The effect of vaccination and reduced
tumour growth on suvival time was not investigated in our
model.
To investigate immune mechanisms possibly involved in
the anti-tumour effects observed immunohistochemical
staining and immunological in vitro assays (CTL and
Elispot assay) were employed. DNA vaccination was re-
quired for lysis rates of >50 % in CTL assays, which,
however, were only observed in a few animals. Similarly,
IFN-γ synthesis as quantified by Elispot assays was higher
in lacZ-vaccinated animals, although this did not reach
statistical significance. Thus, DNA vaccination resulted in
the priming of specific cytotoxic responses as expected from
previous reports [13, 15, 21]. Despite vaccination against
the lacZ antigen, this response was not restricted to lacZ-
expressing cells, but included the parental cell line. We did
not restimulate the lymphocytes with the parental 9L cell
line. Thus, it is unresolved to what extent restimulation with
the antigen proper (lacZ) was required for effective target
cell lysis in those animals revealing a strong CTL response.
The fact, however, that parental 9L (target) cells were
lysed with the same efficacy as 9LlacZ (target) cells
suggests that the lacZ antigen proper was not crucial for
effective restimulation. A possible mechanism is antigen
spreading within the 9L (but not to the syngeneic MADB
106) context.
Notably, intracerebral tumour cell implantation following
vaccination with a control plasmid also elicited 9L tumour-
specific cytotoxic responses in vitro, although this re-
sponse was weaker. Thus, lacZ vaccination may aug-
ment an intrinsic immune response present in the 9L
tumour model occurring independently from prior
immunisation. This response was specific for 9L
tumours and not observed with another syngeneic ade-
nocarcinoma cell line (MADB 106).
Although in a few of the animals pronounced responses
in both in vitro assays had been observed, this response did
not correlate with the anti-tumour effect of prior vaccina-
tion. Thus, cytotoxic T cell responses not detectable by CTL
and Elispot assays or even unidentified effector mechanisms
may play a role in tumour suppression.
This is supported by the fact that the immunohisto-
chemical staining pattern of the different treatment
groups was indistinguishable. Tumour size did not cor-
relate with the degree of lymphocytic infiltration or
activation. Rather heterogeneous staining patterns were
observed within individual tumours, e.g. more pro-
nounced infiltrations around necrotic areas. This is con-
sistent with the ambiguous role proposed for the well-
recognised lymphocytic and microglial infiltrations in
malignant gliomas [8, 14, 19]. In fact, only single cells
stained positive for perforin serving as a marker for
cytolytic activity in situ. We detected immunoreactivity
for CD25 (interleukin-2 receptor alpha chain), known to
be expressed by activated T and B cells, macrophages,
and CD4+ and CD8+ regulatory T cells. As recognised
in recent years, in gliomas and other tumours CD25+
cells often represent regulatory T cells (FoxP3+), and
these cells have been demonstrated to play an important
role in the maintenance of peripheral tolerance [5, 6,
11]. The exact role of different CD25+ cell populations
in tumours, however, is not fully understood. Since
staining for CD25 did not differ between lacZ- and
control-vaccinated animals, we did not attempt to dis-
tinguish different subpopulations of CD25+ cells.
All tumours were densely infiltrated with microglial
cells. Only few microglial cells stained ED-1 positive,
indicating phagocytic activity. Such cells were predomi-
nantly found in necrotic regions. The majority of micro-
glial cells revealed a more ramified morphology. There is
accumulating evidence that these cells are in the service
of the tumour [8, 14, 19]. Microglial cells appear to
promote tumour growth directly (e.g. by producing
growth factors) as well as indirectly by the secretion of
immunosuppressive cytokines (e.g. TGF-β, IL-10) and
the expression of molecules inducing apoptosis in lym-
phocytes (e.g. Fas ligand). The latter factors contribute to
the local and systemic immunosuppression and peripheral
tolerance observed in gliomas.
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Because of this we attempted to augment the anti-tumour
response by intratumoral application of oligonucleotides
containing unmethylated CpG motifs because of their
known macrophage/microglia-activating properties. Such
oligonucleotides exerted no adjuvant effect; on the con-
trary, they resulted in an increase in tumour size in the
9L model. This was observed both following vaccina-
tion against the lacZ gene (data not shown) and in non-
vaccinated animals challenged with naive 9L cells [7].
Furthermore, we evaluated the adjuvant effects of flt-3
ligand and IL-12 expression plasmids that had been
added to the lacZ plasmid used for vaccination (data
not shown). Coadministration of both plasmids did not
increase the anti-tumour response elicited by lacZ vac-
cination only, but, in contrast, there was a trend to the
formation of larger tumours.
In this study we used a therapeutic regimen easily
applicable to patients. Despite a robust anti-tumour effect,
there are several reasons for being cautious with regard
to possible clinical efficacy in glioma patients. We used
an idealised setting with prophylactic vaccination in a
non-infiltrative rodent model that is known to respond
to different immunotherapeutic approaches. Nevertheless,
we could not prevent tumour formation and the failure of
all adjuvants tested thus far reflects how unpredictable
and counter-productive their effects can be. This does not
even touch on the issue of whether vaccination against a
single antigen is sufficient, although, in our model we
did not observe tumour escape due to selection against
the model antigen.
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Comment
This study elegantly demonstrates the potential benefit of the modula-
tion of specialized mechanisms of immune system to treat gliomas. At
the same time, Authors clearly demonstrate how far we are from the
application of this approach in the clinical setting. Cancer immuno-
therapy lets us envisage the possibility to realize the concept of true
"customized medicine". In oncology, this means the development of
treatments that exploit specific molecular differences between normal
and tumor cells; that treatments can be driven by biomarkers that can
differentiate susceptible tumor types from non-susceptible ones sharing
the same or distinct pathological diagnosis; that treatments have limit-
ed off-target effects against normal tissues by exploiting biological
effects only in tumor cells; and that treatments ideally can be combined
to address the inherent heterogeneity of genetic and epigenetic pheno-
types that exist in gliomas. Use of vaccines is one of the most intrigu-
ing approaches to treat brain cancer, but efforts to understand the
pathophysiology of immune-escape of glioma cells are still necessary
to design an effective use in humans
Alfredo Conti
Messina, Italy
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